Face Serum — Technical Specification Overview

Key Technical Parameters #

Serum development conversations usually start in the wrong place. Brands come to us with an active ingredient and a texture reference, and we spend the first meeting backing up to a more fundamental question: what does “this serum” actually mean on paper? Viscosity range, active concentration window, pH tolerance, preservative system, packaging format — without agreed-upon specifications, everything downstream becomes a negotiation instead of a verification. The brands that move fastest through sampling and scale-up are the ones who arrive with a spec framework, even a rough one. This article is the spec framework we use internally when we onboard a new serum brief — adapted for brand partners who want to understand what they’re agreeing to before they sign off on a formula.

The Specification That Drives Everything Else — And Why Brands Usually Miss It #

Viscosity gets the most attention in serum briefs. We get texture references constantly — “like Brand X’s serum,” “a little thicker than water,” “should feel like an essence but layer under a cream.” Those are useful, but they’re not a specification. A specification is a range with measurement conditions.

In our lab, we measure serum viscosity at 25°C using a Brookfield RV-DV2T, spindle S62, 12 RPM, 60-second equilibration. That’s the only way the number means anything. A “light serum” briefed at 500–2,000 mPa·s from one supplier’s datasheets could be measured at 20°C with a different spindle at 6 RPM — and the resulting number tells you nothing about how the product pours from a dropper or layers under moisturizer. We’ve received incoming raw material reports with viscosity specs that are simply not reproducible under our conditions. This happens more often than suppliers want to admit.

But viscosity isn’t actually the spec that drives the most downstream decisions. pH is.

pH controls the ionization state of almost every active in a serum formulation. It determines the efficacy window for acid exfoliation actives, the stability window for ascorbic acid derivatives, the polymer network behavior of carbomers and gums, and — critically — whether a formula tips into EU regulatory reclassification territory. At pH below 3.5, several EU member states treat leave-on leave-on products as borderline medical devices for regulatory notification purposes under EU Cosmetics Regulation 1223/2009. Most brands don’t find out until the distributor flags it.

Our internal protocol, QC-PH-04, requires that all serum formulas be pH-confirmed at three timepoints: fresh batch, 4-week accelerated at 40°C/75% RH, and 8-week accelerated. Drift of more than 0.3 pH units between fresh batch and 8-week accelerated is an automatic reformulation flag. We’ve had formulas pass visual and sensory checks at 8 weeks while the pH had drifted from 5.2 to 4.7 — the consumer experience looks fine, but the preservative efficacy at pH 4.7 is fundamentally different from what was validated at pH 5.2.

The other parameter most briefs underspecify is water activity (Aw). For anhydrous or ultra-low-water serums, Aw governs microbial risk more directly than pH. Below Aw 0.6, most microbial growth is suppressed without a traditional preservative system. Above 0.8, you need a full preservation strategy validated per ISO 11930:2019. Waterless or near-waterless serums for brands targeting preservative-free positioning often fall in the 0.6–0.8 range, which is the ambiguous zone. Our position on that ambiguous zone: we always challenge-test regardless of Aw, because we’ve seen contamination events in the 0.65–0.75 Aw range when packaging seals aren’t airtight.

Supplier Qualification — What to Request and What the Response Tells You #

When we evaluate a new active ingredient supplier for serum-grade material, the first thing we ask for is a Certificate of Analysis (CoA) cross-referenced against their own product specification sheet — not just the CoA in isolation. The gap between what a spec sheet claims and what a CoA reports on a given lot tells you more than either document alone.

For peptide actives, we request HPLC purity data reported as area percentage, minimum 98.0% for cosmetic-grade material, alongside residual solvent analysis. The response time matters: a supplier who sends clean HPLC traces within 48 hours typically has an internal QC workflow. A supplier who needs two weeks to “locate the data” is running on request-only testing. That’s a very different risk profile.

For plant-derived actives — bakuchiol, resveratrol, fermented extracts — we request heavy metal screening (lead, arsenic, cadmium, mercury) per PCPC Guidelines limits, plus country-of-origin documentation if the material is subject to CITES or EU sustainability reporting. On botanical materials, we also ask specifically for pesticide residue panels. We’ve had incoming lots of centella extract test clean for heavy metals but flag on chlorpyrifos residue — a pesticide not commonly included in standard cosmetic screens. We now include it as a default in our incoming inspection protocol for all botanical actives sourced from Southeast Asian suppliers, based on what we’ve seen over roughly 30 incoming lots audited between 2022 and 2024.

For hyaluronic acid, the key qualifier is molecular weight distribution, not average Mw alone. A supplier claiming “high molecular weight HA” should be able to provide GPC (gel permeation chromatography) traces showing tight distribution around 1,500–1,800 kDa with minimal low-Mw fraction. Some suppliers blend grades without disclosing this. When we receive an HA spec that lists only average Mw without distribution data, we treat it as unqualified until GPC data is supplied.

For emollients and carrier oils, we request oxidative stability as peroxide value and anisidine value — not just peroxide value alone. Peroxide value catches primary oxidation; anisidine catches secondary oxidation products that form even after peroxides decompose. A rancid carrier oil can pass peroxide value specifications while carrying secondary oxidation byproducts that cause sensory failure within six months. We still encounter this with suppliers who test to the letter of the spec without understanding why those parameters exist.

Cost-Performance Trade-offs in Serum Formulation #

The decision that most affects final unit cost isn’t actives selection. It’s base system complexity.

A carbomer-thickened aqueous base costs far less to produce than a crosslinked hyaluronate gel or a polyglutamic acid base. The cost differential at production scale varies depending on volume and sourcing, but for a 30ml serum in 10,000-unit runs, the base system alone can represent 15–40% of the total formula cost depending on tier. The actives often get more scrutiny in budget conversations, but a brands asking for a “clean label” thickener instead of carbomer (which some consumers associate with synthetic chemistry, fairly or not) can inadvertently double the base system cost.

Where cheaper is actually correct: for a positioning-led serum where the on-pack story is a single hero active at a validated concentration, a minimalist base — purified water, simple humectant blend, light emollient, carbomer or xanthan gum — is the right call. Adding expensive texture-modifying polymers to a formula that’s going to be marketed on its biotin or niacinamide content doesn’t add consumer-perceivable value. We push back when clients want premium base systems for products where the premium positioning is entirely driven by the active, not the texture experience.

The more nuanced trade-off is between single-layer and encapsulated actives. Encapsulated retinol at 0.1% effective load costs meaningfully more per kilogram of active than free retinol — but when you factor in stability losses over 24 months in a standard dropper bottle, free retinol at the same label claim often doesn’t deliver the same end-of-shelf-life potency. Whether encapsulation makes economic sense depends heavily on packaging format and target shelf life. In an airless pump, free retinol at pH 5.0–5.5 with chelation support can be stable enough that encapsulation becomes an unnecessary premium. In a standard glass dropper with a rubber bulb, we’d almost always recommend encapsulation technology.

The counterargument for budget-tier actives: bakuchiol is a case where paying for the premium supplier matters less than most think. The performance ceiling for bakuchiol across suppliers is relatively similar at 0.5–1.0% use levels, and a 2019 double-blind split-face RCT (n=44, 12 weeks) published in the British Journal of Dermatology showed that 0.5% bakuchiol applied twice daily produced reductions in fine line depth and hyperpigmentation comparable to 0.5% retinol, with significantly lower self-reported irritation scores. The performance driver in that study wasn’t supplier grade — it was concentration and application frequency. Paying a 40% premium for a “patented” bakuchiol extract over a standard-grade material has not shown measurable formulation performance differences in our side-by-side stability and sensory panels.

Technical Deep-Dive: Serum Specification Parameters Across Product Grades #

The most useful thing we can give a brand partner at brief stage is a concrete picture of how serum specifications differ across product tiers. The parameters below reflect our internal benchmarks, validated across multiple production runs.

Internal benchmark data from Mastracare production records; conditions: Brookfield RV-DV2T, S62, 12 RPM, 60s equilibration for viscosity; pH by calibrated electrode at 25°C.

A few things this table doesn’t fully capture.

The viscosity overlap between entry-level and premium tiers is intentional. Premium treatment serums are sometimes low-viscosity by design — high-concentration peptide ampoule formats, for example, intentionally run thin because the delivery strategy relies on rapid penetration rather than occlusive residence time. Viscosity as a quality signal only holds within a product category. Across categories, it’s meaningless.

The preservation tier difference is where we see the most misalignment between brand intent and formulation reality. A brand targeting “clean” positioning often wants a preservative-free claim on a 30ml dropper bottle serum. Getting to ISO 11930 Category A without listed preservatives in a water-based formula at 30ml fill is genuinely difficult. We can usually get there with a combination of low pH, humectant loading, and multifunctional actives like glyceryl caprylate — but the formula design is constrained in ways that affect texture and active selection. We’re still working on a more elegant solution for high-water-content formulas above pH 5.5 that need a clean-label preservation story. Current approach works, but it always involves compromises somewhere.

The 24-month real-time stability requirement for premium tier isn’t just a quality call. For EU market serums, EU Cosmetics Regulation 1223/2009 Article 10 requires a product safety assessment that includes stability data — and while 8-week accelerated data can support initial launch in some markets, premium price positioning invites distributor and regulatory scrutiny that makes real-time data a practical necessity. We initiate 24-month real-time stability at the same time as accelerated testing, not after it. Waiting until accelerated passes wastes six months of clock.

Formulation Notes for Brand Partners #

When you brief us on a new serum, the first questions we ask are about market destination and format — not the active. EU and US destinations require different documentation packages, and knowing that upfront changes how we structure stability testing. A serum destined for NMPA registration in China under the NMPA Cosmetic Regulation framework requires a substantially different technical dossier than one going into a US DTC launch.

The brief mistake we see most often: brands specify an active concentration they’ve seen on a competitor label without knowing whether that concentration is at-batch or end-of-shelf-life. A serum labeled “Vitamin C 15%” may have been manufactured at 18% to compensate for oxidative loss over 24 months. When we receive a brief asking for 15% ascorbic acid in a standard aqueous base, our first response is to ask what the target is at month 24, not at batch release. Those are two different formulas.

On timeline: lab samples take 2–3 weeks from brief sign-off. Accelerated stability (8-week, 40°C/75% RH) runs concurrently with sensory review and any adjustment batches. Twenty-four-month real-time stability is initiated at the same time as the accelerated program. Regulatory documentation preparation can begin as soon as the formula is locked, which we target by week 10–12 for straightforward serums. Complex actives or novel claims add time.

Frequently Asked Questions #

Can we put a pH on the product label, and should we?
A: You can, and some brands do — particularly acid serums where a pH claim is part of the efficacy story. What most brands don’t consider is that once a pH is on the label, it becomes a specification that every batch must meet. If your formula drifts to pH 4.4 at end of shelf-life and the label says 4.5, that’s a non-conformance. We’d recommend reserving label pH claims for formulas where pH control is tight across the full shelf-life window, which in our experience means pH drift of no more than ±0.2 units over 24 months.

Our active supplier says we can use 2% of their ingredient. Why are you suggesting 0.5%?
A: Supplier recommended usage rates are typically the upper boundary of what they’ve tested for safety, not the concentration that performs best in a finished formula. At 2%, several common actives — niacinamide included — can interact with other formula components in ways that cause yellowing, precipitation, or sensory off-notes that weren’t present at 0.5–1.0%. We’d always run a compatibility matrix before committing to the supplier’s top-line recommendation.

What happens if our serum fails ISO 11930 challenge testing?
A: We reformulate — but how we reformulate depends on where it failed. Category A requires no growth of the challenge organisms; Category B permits limited recovery. If a formula fails outright, the most common causes we see are pH too high for the preservation system to function, or water activity in the range where partial inhibition creates selection pressure. A failure at week 8 challenge test isn’t a disaster, but it means we’re back to formulation before any stability clock is meaningful. Budget 4–6 additional weeks.

What’s your MOQ for a serum with a custom active blend?
A: For a standard liquid serum in stock packaging, our minimum production run is 3,000 units. Custom active blends with pre-dispersed or encapsulated components typically require 5,000 units as a minimum to keep unit cost viable. Lab sample quantities (10–30 units) for brief review and sensory evaluation are available before production commitment.

Should we lock packaging before or after the formula is finalized?
A: After — always. Packaging compatibility testing is a formula-specific exercise. Changing from a glass dropper to an airless pump after formula lock means repeating extraction testing for all components in contact with the formula, and potentially reformulating if the silicone or plastic contacts cause active migration or sensory contamination. We’ve had to redo compatibility panels at late stage on two separate projects where packaging changed post-stability-lock. It delays launch by 6–10 weeks each time. Lock packaging early, but do not finalize it before the formula base system is confirmed.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.